# Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196)

> **NCT01117220** · PHASE3 · WITHDRAWN · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.**

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Placebo
- **DRUG:** Ziprasidone Oral Capsules

## Key facts

- **NCT ID:** NCT01117220
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-06
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01117220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01117220, "Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01117220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*